scholarly journals On Study of Immune Response to Tumor Cells in Prey-Predator System

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Gurpreet Kaur ◽  
Naseem Ahmad
Keyword(s):  
Immune Response ◽  
Tumor Cells ◽  
Deterministic Model ◽  
Cellular Level ◽  
Resting Cells ◽  
Global Stability Analysis ◽  
System A ◽  
Specific Antigens ◽  
The Mathematical Model ◽  
Predator System

This paper aims to develop the mathematical model that explores the immune response to a tumor system as a prey-predator system. A deterministic model defining the dynamics of tumor growth progression and regression has been analyzed. Our analysis indicates the tumor recurring and dormancy on the cellular level in combination with resting and hunting cells. The model considered in the present study is a generalization of El-Gohary (2008) by introducing the Michaelis-Menten function. This function describes the stimulation process of the resting cells by the tumor cells in the presence of tumor specific antigens. Local and global stability analysis have been performed along with the numerical simulation to support our findings.

scholarly journals Assessment of the Efficient Strategies for Applying Antitumor Viral Vaccine Therapy Based On Mathematical Modeling

2019 ◽  
Vol 14 (1) ◽  
pp. 34-53 ◽  
Author(s):  
N.A. Babushkina ◽  
E.A. Kuzina ◽  
A.A. Loos ◽  
E.V. Belyaeva
Keyword(s):  
Mathematical Model ◽  
Immune Response ◽  
Tumor Cells ◽  
Tumor Size ◽  
Single Shot ◽  
Complete Elimination ◽  
Antitumor Therapy ◽  
Viral Vaccine ◽  
Two Stages ◽  
The Mathematical Model

The paper presents the mathematical description of the two stages of tumor cells’ death as a result of immune response after antitumor viral vaccine introduction. This mathematical description is presented by the system of nonlinear equations implemented in the MatLab-Simulink system. As a result of the computing experiment, two strategies for effective application of the antitumor viral vaccine were identified. The first strategy leads to complete elimination of the tumor cells after a single-shot administration of the vaccine. The second strategy makes it possible to stabilize tumor size through the recurrent introductions of the vaccine. Using the mathematical model of antitumor therapy, appropriate dosages were identified based on the number of tumor cells that die at the two stages of immune response. Dynamics of tumor growth for the two strategies of the viral vaccine application was forecasted based on the mathematical model of antitumor therapy with discontinuous trajectories of tumor growth. The computing experiments made it possible to identify initial tumor size at the start of the therapy and the dosages that allow complete elimination of the tumor cells after the single-shot introduction. For the second strategy, dosages and intervals between recurrent vaccine introductions required to stabilize tumor size at the initial level were also identified. The proposed approach to exploring the effectiveness of vaccine therapy may be applied to different types of experimental tumors and antitumor vaccines.

Numerical analysis of fractional-order tumor model

2015 ◽  
Vol 08 (05) ◽  
pp. 1550069 ◽  
Author(s):  
Ayesha Sohail ◽  
Sadia Arshad ◽  
Sana Javed ◽  
Khadija Maqbool
Keyword(s):  
Mathematical Model ◽  
Immune Response ◽  
Fractional Order ◽  
Interleukin 2 ◽  
Tumor Model ◽  
Graphical Analysis ◽  
System A ◽  
The Stability ◽  
The Mathematical Model ◽  
Limiting Values

In this paper, the tumor-immune dynamics are simulated by solving a nonlinear system of differential equations. The fractional-order mathematical model incorporated with three Michaelis–Menten terms to indicate the saturated effect of immune response, the limited immune response to the tumor and to account the self-limiting production of cytokine interleukin-2. Two types of treatments were considered in the mathematical model to demonstrate the importance of immunotherapy. The limiting values of these treatments were considered, satisfying the stability criteria for fractional differential system. A graphical analysis is made to highlight the effects of antigenicity of the tumor and the fractional-order derivative on the tumor mass.

Natural Macromolecules with Protective and Antitumor Activity

2018 ◽  
Vol 18 (5) ◽  
pp. 675-683 ◽  
Author(s):  
Cioanca Oana ◽  
Trifan Adriana ◽  
Cornelia Mircea ◽  
Scripcariu Dragos ◽  
Hancianu Monica
Keyword(s):  
Immune Response ◽  
Antitumor Activity ◽  
Tumor Cells ◽  
Biological Activities ◽  
Molecular Size ◽  
Plant Lectins ◽  
Natural Toxins ◽  
Glycosidic Bonds ◽  
Novel Drug

This review summarizes the literature data regarding plant lectins as novel drug sources in the prevention or treatment of cancer. Moreover, such compounds have been described as natural toxins that possess different biological activities (cytotoxic, antitumor, antimutagenic and anticarcinogenic properties). This activity depends greatly on their structure and affinity. Most of the mushroom heterosides are known as β-glucans with β-(1→3)-glycosidic bonds. It is thought that their conformation, bonds, molecular size can modulate the immune response by triggering different receptors. The mechanism on normal and tumor cells of various plant and mushroom polysaccharides and lectins is briefly presented in this paper.

scholarly journals NLRP7 Promotes Choriocarcinoma Growth and Progression through the Establishment of an Immunosuppressive Microenvironment

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2999
Author(s):  
Deborah Reynaud ◽  
Roland Abi Nahed ◽  
Nicolas Lemaitre ◽  
Pierre-Adrien Bolze ◽  
Wael Traboulsi ◽  
...  
Keyword(s):  
Immune Response ◽  
Tumor Cells ◽  
Major Gene ◽  
Critical Role ◽  
Orthotopic Model ◽  
Independent Manner ◽  
Maternal Immune Response ◽  
The Impact

The inflammatory gene NLRP7 is the major gene responsible for recurrent complete hydatidiform moles (CHM), an abnormal pregnancy that can develop into gestational choriocarcinoma (CC). However, the role of NLRP7 in the development and immune tolerance of CC has not been investigated. Three approaches were employed to define the role of NLRP7 in CC development: (i) a clinical study that analyzed human placenta and sera collected from women with normal pregnancies, CHM or CC; (ii) an in vitro study that investigated the impact of NLRP7 knockdown on tumor growth and organization; and (iii) an in vivo study that used two CC mouse models, including an orthotopic model. NLRP7 and circulating inflammatory cytokines were upregulated in tumor cells and in CHM and CC. In tumor cells, NLRP7 functions in an inflammasome-independent manner and promoted their proliferation and 3D organization. Gravid mice placentas injected with CC cells invalidated for NLRP7, exhibited higher maternal immune response, developed smaller tumors, and displayed less metastases. Our data characterized the critical role of NLRP7 in CC and provided evidence of its contribution to the development of an immunosuppressive maternal microenvironment that not only downregulates the maternal immune response but also fosters the growth and progression of CC.

scholarly journals Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3386
Author(s):  
Bart Spiesschaert ◽  
Katharina Angerer ◽  
John Park ◽  
Guido Wollmann
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Tumor Cells ◽  
Small Molecule ◽  
Antiviral Immunity ◽  
Oncolytic Viruses ◽  
Antitumor Immune Response ◽  
Antiviral Responses ◽  
Small Molecule Therapeutics ◽  
Immunosuppressive Factors

The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.

scholarly journals The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3596
Author(s):  
Reza Bayat Mokhtari ◽  
Manpreet Sambi ◽  
Bessi Qorri ◽  
Narges Baluch ◽  
Neda Ashayeri ◽  
...  
Keyword(s):  
Immune System ◽  
Cancer Immunotherapy ◽  
Tumor Cells ◽  
Tumor Antigens ◽  
Response Rates ◽  
Viral Proteins ◽  
Tumor Rejection ◽  
Therapeutic Approaches ◽  
Patient Response ◽  
Specific Antigens

Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection. These tumor-associated antigens include tumor-specific shared antigens, differentiation antigens, protein products of mutated genes and rearrangements unique to tumor cells, overexpressed tissue-specific antigens, and exogenous viral proteins. However, the development of effective therapeutic approaches has proven difficult, mainly because these tumor antigens are shielded, and cells primarily express self-derived antigens. Despite innovative and notable advances in immunotherapy, challenges associated with variable patient response rates and efficacy on select tumors minimize the overall effectiveness of immunotherapy. Variations observed in response rates to immunotherapy are due to multiple factors, including adaptative resistance, competency, and a diversity of individual immune systems, including cancer stem cells in the tumor microenvironment, composition of the gut microbiota, and broad limitations of current immunotherapeutic approaches. New approaches are positioned to improve the immune response and increase the efficacy of immunotherapies, highlighting the challenges that the current global COVID-19 pandemic places on the present state of immunotherapy.

A Summary of the Third Global Interferon-γ Release Assay Symposium

2013 ◽  
Vol 34 (6) ◽  
pp. 619-624 ◽  
Author(s):  
Antonino Catanzaro ◽  
Charles Daley
Keyword(s):  
Immune Response ◽  
Tuberculin Skin Test ◽  
Skin Test ◽  
Interferon Γ ◽  
Enzyme Linked Immunosorbent Assay ◽  
In Vitro Tests ◽  
The Third ◽  
Specific Antigens ◽  
Ifn Γ

Studies over the past several decades have dramatically increased our understanding of the immune response to Mycobacterium tuberculosis infection, and advances in proteomics and genomics have led to a new class of immune-diagnostic tests, termed interferon-γ (IFN-γ) release assays (IGRAs), which appear to obviate many of the problems encountered with the tuberculin skin test (TST). Worldwide, 2 IGRAs are currently commercially available. QuantiFERON-TB Gold In-Tube (Cellestis) is a third-generation product that uses an enzyme-linked immunosorbent assay to measure IFN-γ generated in whole blood stimulated with M. tuberculosis–specific antigens. T-Spot-TB (Oxford Immunotec) employs enzyme-linked immunosorbent spot technology to enumerate the number of purified lymphocytes that respond to M. tuberculosis–specific antigens by producing IFN-γ. These in vitro tests measure the host immune response to M. tuberculosis–specific antigens, which virtually eliminates false-positive cross reactions caused by bacillus Calmette-Guérin vaccination and/or exposure to environmental nontuberculous mycobacteria that plague the interpretation and accuracy of the tuberculin skin test (TST). The high specificity of IGRAs, together with sensitivity commensurate with or better than that of the TST, promises an accurate diagnosis and the ability to focus tuberculosis-control activities on those who are actually infected with M. tuberculosis. The Third Global Symposium was held over a 3-day period and was presented by the University of California, San Diego, Continuing Medical Education department; slides and sound recordings of each presentation are available at http://cme.ucsd.edu/igras/syllabus.html. A moderated discussion is also available at http://cme.ucsd.edu/igrasvideo. This document provides a summary of the key findings of the meeting, specifically focusing on the use of IGRAs in screening healthcare worker populations.

IMMU-44. AN IMMUNOTHERAPEUTIC VACCINE COMPOSED OF IRRADIATED WHOLE TUMOR CELLS PULSED WITH MANNAN-BAM, TLR LIGANDS AND ANTI-CD40 ANTIBODY INDUCES POTENT IMMUNE RESPONSE IN PRECLINICAL GBM ANIMAL MODEL

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi102-vi102
Author(s):  
Herui Wang ◽  
Rogelio Medina ◽  
Juan Ye ◽  
Pashayar Lookian ◽  
Ondrej Uher ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Tumor Cells ◽  
T Lymphocyte ◽  
Cd8 T Cells ◽  
Therapeutic Efficacy ◽  
Poly I:C ◽  
Control Group ◽  
Complete Regression ◽  
Adaptive Immune

Abstract Despite numerous therapeutic advances, the treatment of glioblastoma multiforme (GBM) remains a challenge, with current 5-year survival rates estimated at 4%. Multiple characteristic elements of GBM contribute to its treatment-resistance, including its low immunogenicity and its highly immunosuppressive microenvironment that can effectively disarm adaptive immune responses. Hence, therapeutic strategies that aim to boost T-lymphocyte mediated responses against GBM are of great therapeutic value. Herein, we present a therapeutic vaccination strategy that promotes the phagocytosis of tumor cells, enhances tumor antigen presentation, and induces a tumor-specific adaptive immune response. This strategy consists of vaccinations with irradiated whole tumor cells (rWTC) pulsed with phagocytic agonists (Mannan-BAM), TLR ligands [LTA, Poly (I:C), and R-848], and anti-CD40 antibody (collectively abbreviated as rWTC-MBTA). We evaluated the therapeutic efficacy of rWTC-MBTA strategy in a mouse syngeneic GL261 orthotopic GBM tumor model. rWTC-MBTA or vehicle control were administered subcutaneously over the right foreleg three days after intracranial injection of GL261 cells. Complete regression (CR) of intracranial tumors was achieved in 70% (7/10) of rWTC-MBTA treated animals while none survived in the control group. Immunophenotyping analyses of peripheral lymph nodes and brain tumors of rWTC-MBTA treated mice demonstrated: (1) increased mature dendritic cells and MHC II+ monocytes; (2) increased effector (CD62L-CD44+) CD4-T and CD8-T cells; (3) increased cytotoxic IFNγ-, TNFα-, and granzyme B-secreting CD4-T and CD8-T cells. Of note, the therapeutic efficacy of rWTC-MBTA disappeared in CD4-T and/or CD8-T lymphocyte depleted mice. Three mice that achieved CR were rechallenged with 50k GL261 cells intracranially 14 months after the last rWTC-MBTA treatment and all rechallenged animals resisted GL261 tumor development, confirming the establishment of long-term immunological memory against GL261 tumor cells. Collectively, our study demonstrated that rWTC-MBTA strategy can effectively activate antigen presenting cells and induce more favorable T-cell signatures in the GBM tumors.

scholarly journals Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response

Oncotarget ◽  
2018 ◽  
Vol 9 (40) ◽  
pp. 25808-25825 ◽  
Author(s):  
Felipe V. Pereira ◽  
Amanda Campelo L. Melo ◽  
Jun Siong Low ◽  
Íris Arantes de Castro ◽  
Tárcio T. Braga ◽  
...  
Keyword(s):  
Immune Response ◽  
Antitumor Activity ◽  
Tumor Cells ◽  
Protective Immune Response
Sign in / Sign up

Export Citation Format

Share Document